Indication
For treatment of adult patients (aged 18 years and over) with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (ALL).
Medicine details
- Medicine name:
- obecabtagene autoleucel (Aucatzyl)
- SMC ID:
- SMC2917
- Pharmaceutical company
- Autolus Therapeutics
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- TBC
- SMC meeting date:
- TBC